Table 5. Clinical characteristics in Stevens-Johnson syndrome and toxic epidermal necrolysis according to the causative drugs.

Characteristic		Antibiotics (n=28)	Allopurinol (n=20)	AED (n=17)	NSAIDs (n=15)	Acetaminophen (n=2)	Others (n=10)
Age (yr)		60.5±18.8	66.5±15.3	55.9±22.7	55.8±23.0	37.5±9.2	51.6±23.3
Female sex		15 (53.6)	7 (35.0)	4 (23.5)	8 (53.3)	0 (0)	4 (40.0)
Type of SJS/TEN
	SJS	16 (57.2)	16 (80.0)	15 (88.2)	7 (46.7)	1 (50.0)	8 (80.0)
	SJS/TEN overlap	6 (21.4)	2 (10.0)	1 (5.9)	2 (13.3)	1 (50.0)	1 (10.0)
	TEN	6 (21.4)	2 (10.0)	1 (5.9)	6 (40.0)*	0 (0)	1 (10.0)
Involved BSA		24.9±23.6	11.3±15.2	7.1±9.8*	47.5±39.5*	10±7.1	20.8±28.0
SCORTEN		2.1±1.1	1.9±1.0	1.2±1.0	1.9±1.2	0.5±1.7	1.3±0.8
Latent period (day)		13.1±9.4	21.6±10.4	16.4±9.3	14.9±7.7	5±1.4	18.5±11.2
Route of administration
	Oral	11 (39.2)	20 (100)	17 (100)	11 (73.3)	2 (100)	8 (80.0)
	IV or SC	17 (60.8)	0 (0)	0 (0)	4 (26.7)	0 (0)	1 (10.0)
	Eyedrop	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (10.0)
Treatment options
	Supportive	4 (14.3)	1 (5.0)	1 (5.9)	1 (6.7)	0 (0)	0 (0)
	Corticosteroid or IVIG	18 (64.3)	16 (80.0)	15 (88.2)	13 (86.6)	2 (100)	6 (60.0)
	Corticosteroid and IVIG	6 (21.4)	3 (15.0)	1 (5.9)	1 (6.7)	0 (0)	4 (40.0)
Duration of treatment (day)		17.7±10.5	18.2±9.1	15.2±9.8	20.4±10.7	19.5±7.8	18.4±10.4
Clinical course
	Recovery	23 (82.1)	17 (75.0)	17 (100)	15 (100)	2 (100)	10 (100)
	Death	5 (17.9)	3 (15.0)	0 (0)	0 (0)	0 (0)	0 (0)

Values are presented mean ± standard deviation or number (%).

SJS, Stevens-Johnson syndrome; TEN, Toxic epidermal necrolysis; AED, antiepileptic drug; NSAIDs, nonsteroidal anti-inflammatory drugs; BSA, body surface area; SCORTEN, a severity-of-illness score for toxic epidermal necrolysis; IV, intravenous; SC, subcutaneous; IVIG, intravenous immunoglobulin.

^*p < 0.05 was considered statistically significant.